Ispire Technology Inc.·Consumer Defensive

Partnership combines pharmaceutical-grade manufacturing with Ispire's global platform to accelerate entry into one of the fastest-growing nicotine segments LOS ANGELES, May 12, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) ("Jincheng Pharma"), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.

Ispire Technology NASDAQ: ISPR executives told investors the company's fiscal third quarter of 2026 marked a “turning point,” citing tighter operating discipline, early signs of liquidity improvement, and several near- and long-term initiatives aimed at expanding its presence in nicotine manufacturing and compliance technology markets. Get Ispire Technology alerts:Sign UpManagement highlights Malaysia platform and phased growth roadmap Co-CEO Michael Wang said the company's business has “stabilized” following a transition away from lower-quality revenue.

Ispire Technology Inc. (ISPR) Q3 2026 Earnings Call Transcript

Ispire Technology Inc. (ISPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.19 per share a year ago.

Cash Increased Sequentially by $468,000 to $18 Million Plans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026 Business Stabilized Following Strategic Repositioning Phased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass Technology LOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (Nasdaq: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026. Michael Wang, Co-Chief Executive Officer of Ispire, commented, "This quarter reflects the successful stabilization of our business and with cash growing sequentially by $468,000 to $18 million, we are now executing against a phased roadmap, with near-term revenue drivers already in production and transformative technology opportunities on the horizon: Our Malaysia manufacturing is live today, giving us a 25% tariff advantage over China in a ~$73B global vape market.

LOS ANGELES, May 1, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, May 7, 2026, to discuss the Company's financial results for its fiscal third quarter ended March 31, 2026. To listen to the conference call, please dial in using the information below.
Ispire Technology Inc. manufactures e-cigarettes and cannabis vaping products. The company was founded in 2019 and is based in Los Angeles, California. Ispire Technology Inc. operates as a subsidiary of Pride Worldwide Investment Limited
Consumer Defensive
Tobacco
98
2023-04-04
1.83